5 Key Takeaways

• 1

  A retrospective study analyzed 331 blood samples from 42 patients with stage IA lung adenocarcinoma after surgery.

• 2

  Whole-genome sequencing and an AI-supported algorithm detected circulating tumor DNA with 75% sensitivity and 83% specificity for recurrence.

• 3

  Among 12 patients with recurrence, 9 had detectable circulating tumor DNA, and 6 had a positive test a median of 16.7 months before clinical or imaging confirmation.

• 4

  Whole-genome sequencing also helped distinguish recurrent disease from a second primary lung tumor.

• 5

  The small retrospective study requires prospective validation, and further research must assess integration with imaging and effects on patient outcomes.